Monitor TONMYA's prescription growth and payer coverage progress as key indicators of commercial success. The expanded cash runway provides visibility through Q1 2027, reducing near-term dilution risk, but continued high burn rate warrants monitoring of future capital needs.
Price Chart
Executive Summary
Tonix Pharmaceuticals reported its 2025 financial results, highlighting the commercial launch of TONMYA for fibromyalgia, which generated $1.4 million in revenue post-launch. The company reported full-year revenue growth to $13.1 million and raised $28.6 million in capital, ending 2025 with $207.6 million in cash. Despite increased R&D and SG&A expenses, the company extended its cash runway into Q1 2027.
Key Financial Metrics
Key Facts
- Launched TONMYA for fibromyalgia on November 17, 2025, with $1.4 million in sales from launch to year-end
- Full-year 2025 revenue increased 29.8% to $13.1 million from $10.1 million in 2024
- Net loss widened to $124.0 million in 2025 from $130.0 million in 2024, but on a per-share basis improved to $14.57 from $176.60
- Completed $20.0 million registered direct offering with Point72 and raised $8.6 million via ATM, ending 2025 with $207.6 million in cash
- Deployed 90-person sales force and reported over 1,500 healthcare providers prescribed TONMYA by February 27, 2026
Financial Impact
Revenue increased by $3.0 million year-over-year to $13.1 million, while cash position grew by $108.8 million to $207.6 million. However, operating expenses increased significantly with SG&A up 119% to $87.7 million
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| TONMYA | $1.4M | — |
| Zembrace, SymTouch, Tosymra | $11.7M | +15.8% |
Risk Factors
- High cash burn rate with net cash used in operations increasing to $99.8 million in 2025
- Significant increase in SG&A expenses to $87.7 million, up 119% year-over-year, driven by TONMYA commercialization
- TONMYA revenue generation lags prescriptions due to bridge prescriptions not immediately generating revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001999371-26-005742 |
| Document: tonix-8k_031326.htm | 0001999371-26-005742 |
| Document: 0001999371-26-005742-index-headers.html | 0001999371-26-005742 |
| Document: 0001999371-26-005742-index.html | 0001999371-26-005742 |
| Document: 0001999371-26-005742.txt | 0001999371-26-005742 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | Press Release | $5.73 | awaiting T+20 | — | $5.30 (−7.42%) |
Oct 15, 2026 11d ago | 8-K | $6.42 | awaiting T+20 | — | $5.30 (−17.37%) |
Oct 2, 2026 23d ago | 8-K | $8.07 | awaiting T+20 | — | $5.30 (+34.26%) |
Sep 22, 2026 4w ago | 8-K | $10.59 $5.78 | ▼ −45.42% | ▼ −44.86% | $5.30 (−49.91%) |
Sep 8, 2026 6w ago | 8-K | $13.16 $7.70 | ▼ −41.49% | ▼ −43.46% | $5.30 (−59.69%) |
Aug 10, 2026 11w ago | 8-K | $12.59 $13.16 | ▲ +4.53% | ▲ +5.44% | $5.30 (−57.86%) |
Aug 10, 2026 11w ago | Press Release | $12.59 $13.16 | ▲ +4.53% | ▲ +5.44% | $5.30 (−57.86%) |
Aug 3, 2026 12w ago | 8-K | $10.67 $14.10 | ▲ +32.15% | ▲ +30.91% | $5.30 (−50.28%) |
Jul 27, 2026 13w ago | Press Release | $10.37 $12.45 | ▲ +20.06% | ▲ +16.76% | $5.30 (−48.84%) |
Jul 13, 2026 15w ago | 8-K | $11.71 $12.59 | ▲ +7.56% | ▲ +4.38% | $5.30 (−54.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers